Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684759 | 1.00 | USP2 (0.55) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL25996474 | 0.94 | USP2 (0.45) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL12754870 | 0.92 | FFAR1 (0.50) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL8830378 | 0.91 | USP2 (0.59) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL8114951 | 0.91 | USP2 (0.59) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL11795656 | 0.91 | USP2 (0.59) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL8114954 | 0.91 | USP2 (0.59) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL8601496 | 0.91 | USP2 (0.59) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL25996472 | 0.91 | USP2 (0.42) | USP2HTTFFAR4FFAR1GPR84 | |
| SCHEMBL4249107 | 0.90 | USP2 (0.65) | USP2HTTFFAR4FFAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250255938-A1 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | THORNHILL THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250242039-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | THORNHILL THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240299565-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | APPLIED MOLECULAR TRANSPORT INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240226243-A9 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | THORNHILL THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240207372-A1 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | APPLIED MOLECULAR TRANSPORT INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240131118-A1 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | APPLIED MOLECULAR TRANSPORT INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4316586-A2 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | Applied Molecular Transport Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4082558-B1 | TOXIN-DERIVED DELIVERY CONSTRUCTS FOR ORAL DELIVERY | APPLIED MOLECULAR TRANSPORT INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230158163-A1 | TOXIN-DERIVED DELIVERY CONSTRUCTS | THORNHILL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20070066813-A1 | Modified transferrin fusion proteins | BIOREXIS TECHNOLOGY, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2006096515-A2 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205037-A1 | Modified transferrin fusion proteins | BIOREXIS PHARMACEUTICAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1611093-A4 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORP (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006049983-A2 | PEPTIDE YY MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1611093-A2 | MODIFIED TRANSFERRIN FUSION PROTEINS | Biorexis Pharmaceutical Corporation (US) | 2006-01-04 | — | — | EP | disclosed |
| CN-1713920-A | Modified transferrin fusion proteins | BIOREXIS PHARMACEUTICAL CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| WO-2004020405-A2 | MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019872-A2 | ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS | BIOREXIS PHARMACEUTICAL CORPORATION (US) | 2004-03-11 | — | — | WO | disclosed |
| US-5360790-A | Method and formulations for the therapy of acute renal failure | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066813-A1 | Modified transferrin fusion proteins | TFRC, FTH1, F13B | USP2 3235/4885HTT 1711/4885FFAR4 666/4885 |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | USP2 3171/4885HTT 2846/4885FFAR4 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.